Oruka Therapeutics Inc. (ORKA) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Oruka Therapeutics Inc. (NASDAQ: ORKA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $95.43 (-1.49% 1D, market cap $6.41B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ORKA ranks #226 in composite RQD confidence.
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ORKA carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.8%. By comparison, LNTH (Lantheus Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 28.0x, ROIC 20.3%, cap $6.56B) and NEOG (Neogen Corporation) posts a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).
Per ORKA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000907654), Oruka Therapeutics Inc. generated $341.7M in revenue (+38.5% YoY), -$105.4M in net income, and -$88.4M in free cash flow against $488.6M in total assets and $7.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±10.3% realized swing band)
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ORKA currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($88.03) and Max Pain ($100.20) forces dealer call-delta covering toward $121.30.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Oruka Therapeutics Inc. (ORKA) slipped -1.49% to $95.43, trading at 78% of its 52-week range ($25.23 – $115.52). Stretched risk/reward at current multiples (-19% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Singapore report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
The Motley Fool report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.
Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $165 price target.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +38.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ORKA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ORKA. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Oruka Therapeutics Inc. (ORKA) ranks #226 by composite RQD confidence (53/100, grade D+) and #139 by equity capitalization ($6.41B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while LNTH leads on capital efficiency and profitability with 20.3% ROIC and 61.1% gross margin. LNTH currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with ORKA at 53/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ORKA
ACTIVE
Oruka Therapeutics Inc. | D+ | 53/100 | — | — | -18.8% | -1.49% | $6.41B | Benchmark Subject |
| LNTH Lantheus Holdings Inc. | B+ | 76/100 | 28.0x | 61.1% | 20.3% | -0.15% | $6.56B | /lnth-vs-orka → |
| NEOG Neogen Corporation | D | 47/100 | — | 46.9% | -0.6% | 0.00% | $2.58B | /neog-vs-orka → |
| CLDX Celldex Therapeutics Inc. | E | 29/100 | — | 87.1% | -35.0% | -3.52% | $2.36B | /cldx-vs-orka → |
| NTLA Intellia Therapeutics Inc. | E | 25/100 | — | — | -35.0% | -6.50% | $1.75B | /ntla-vs-orka → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Oruka Therapeutics Inc. (ORKA) reported GAAP revenue of $341.7M (+38.5% vs. FY2024 revenue of $246.7M , and +1572.8% cumulative change since FY2023) , GAAP net income of -$105.4M, operating cash flow of -$88.2M, and free cash flow of -$88.4M (-52.4% YoY). On the balance sheet, ORKA closed FY2025 with $488.6M in total assets against $7.5M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $341.7M | -$105.4M | -$88.2M | -$88.4M | $488.6M | $7.5M |
| FY2024 (FY) | 2024-12-31 | $246.7M | -$83.7M | -$57.8M | -$58.0M | $396.0M | $6.2M |
| FY2023 (FY) | 2023-12-31 | $20.4M | -$5.3M | -$5.0M | -$5.0M | $3.52B | $823.6M |
As of 2026-11-03, Oruka Therapeutics Inc. (NASDAQ: ORKA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $95.43 (-1.49% 1D, market cap $6.41B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ORKA ranks #226 in composite RQD confidence.
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), ORKA carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.8%. By comparison, LNTH (Lantheus Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 28.0x, ROIC 20.3%, cap $6.56B) and NEOG (Neogen Corporation) posts a D grade (47/100 RQD, P/E N/A, ROIC -0.6%, cap $2.58B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).
Per ORKA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000907654), Oruka Therapeutics Inc. generated $341.7M in revenue (+38.5% YoY), -$105.4M in net income, and -$88.4M in free cash flow against $488.6M in total assets and $7.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ORKA last traded at $95.43 (-1.49% on volume of 654,389 shares), positioning the stock +8.41% above its 50-day simple moving average ($88.03) and +35.96% above its 200-day simple moving average ($70.19). Across its 52-week range of $25.23 to $115.52, ORKA sits at the 77.7% percentile with a 14-day RSI of 67.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.3% ($85.60 to $105.26).
Oruka Therapeutics Inc. (ORKA) earns a live Roarable RQD composite score of 53/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $95.43 (-1.49% 1D, market capitalization $6.41B).
Oruka Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, classified under the industry Biotechnology: In Vitro & In Vivo Diagnostic Substances. Gross margin is recorded as 0% in the market data.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Oruka Therapeutics Inc. (ORKA) reported $341.7M in annual revenue (up from $246.7M in FY2024, +38.5% YoY) and -$105.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($20.4M revenue, -$5.3M net income) through FY2025, ORKA scaled operating cash flow to -$88.2M and free cash flow to -$88.4M, backed by $488.6M in total assets against $7.5M in total debt.
Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), ORKA carries a macro regime beta of 1.13 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Oruka Therapeutics Inc. (ORKA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
The Motley Fool report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Oruka Therapeutics Inc. (ORKA) market action, institutional positioning, and fundamental catalysts.
Picked up a starter position in ORKA in my $100K Virtual Cash book at $96.87. Institutional accumulation and options positioning score 17 of 20 in the RQD rating, with a low debt/equity ratio of 0.01 supporting the balance sheet.. Trading inside a $25.23–$115.52 52-week range with -1.38% FCF yield gives solid downside support if Biotechnology: In Vitro & In Vivo Diagnostic Substances multiples expand this quarter.
@CashFlowKing Agree on the RQD 53/100 quality, though with 1.13 beta I'm scaling in with half-size at $96.87 and keeping dry powder in case we test $90.09.
Negative free cash flow of -$88.4M in FY 2025 against $46.9M of cash, with EPS (TTM) of -1.59 and ROIC of -18.8%.. Look at the math on ORKA: paying 28.0x forward P/E for -18.8% ROIC and -6.8% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $85.25 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: